Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ACCG-2671

Other · developed by Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics

Phase 1/2 Most advanced trial
GPCR Developer
1 Registered trials

What is ACCG-2671?

ACCG-2671 is a drug studied in obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics (GPCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07815678 Phase 1/2 Obesity Recruiting GPCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obesity

More from Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics

Aleniglipron Phase 3

Follow GPCR, the company behind ACCG-2671

See GPCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GPCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.